Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
Improvement of health status with acoramidis in patients with wild-type and variant transthyretin amyloid cardiomyopathy: KCCQ domains analysis from the ATTRibute-CM study
To evaluate the effects of acoramidis on KCCQ domain and summary scores in participants with ATTRwt-CM and ATTRv-CM.
In ATTRibute-CM, acoramidis preserved HF-related health status versus placebo in both ATTRwt-CM and ATTRv-CM subgroups, reinforcing the clinically meaningful, patient-centred benefits of acoramidis.
Acoramidis showed consistent separation exceeding the MCID threshold for meaningful improvement versus placebo across nearly all KCCQ individual domain scores in both subgroups.
Acoramidis provided a large (> 20 points) magnitude of benefit in several KCCQ domains in ATTRv-CM, which may reflect the high disease burden in this subgroup.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
